Literature DB >> 20797569

Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.

Nosratola D Vaziri1.   

Abstract

Chronic kidney disease (CKD) is associated with a high risk of death from cardiovascular disease. Inflammation, oxidative stress, and dyslipidemia, which are common consequences of CKD, contribute to the pathogenesis of atherosclerosis and cardiovascular disease in this population. Dyslipidemia of CKD is characterized by diminished plasma high density lipoprotein (HDL) concentration, impaired HDL anti-oxidant and anti-inflammatory activities, and elevated plasma triglyceride, very low density lipoprotein (VLDL), intermediate density lipoprotein, chylomicron remnants, and oxidized lipids and lipoproteins. The constellation of inflammation, HDL deficiency, and oxidative modification of lipoproteins can cause atherosclerosis and progression of renal disease. We have recently found lipid accumulation in the remnant kidney and the wall of aorta in rats with CKD induced by 5/6 nephrectomy. This was mediated by up-regulation of scavenger receptors involved in the influx of oxidized lipids or lipoproteins, tubular reabsorption of lipid binding proteins through megalin-cubilin complexes, upregulation of fatty acid synthesis, and downregulation of fatty acid oxidation pathways. The combination of increased lipid influx, elevated production and reduced catabolism of lipids, and impaired HDL-mediated reverse cholesterol transport can promote atherosclerosis, glomerulosclerosis, and tubulointerstitial damage. Although statins can be effective in slowing CKD progression in patients with mild-to-moderate CKD, they have consistently failed to mitigate oxidative stress, inflammation, HDL deficiency, or cardiovascular mortality in the end-stage renal disease populations. Similarly, high doses of antioxidant vitamins have failed to either ameliorate oxidative stress, inflammation, or improve overall mortality in end-stage renal disease. This article is intended to provide a brief review of the effects of CKD on HDL structure and function and pathways of lipid influx, efflux, synthesis, and catabolism in the artery wall and the diseased kidney. Copyright 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20797569     DOI: 10.1053/j.jrn.2010.05.010

Source DB:  PubMed          Journal:  J Ren Nutr        ISSN: 1051-2276            Impact factor:   3.655


  36 in total

Review 1.  Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.

Authors:  Nosratola D Vaziri
Journal:  Kidney Int       Date:  2016-04-26       Impact factor: 10.612

2.  Carbamylated Lipoproteins and Progression of Diabetic Kidney Disease.

Authors:  Kathryn C B Tan; Ching-Lung Cheung; Alan C H Lee; Joanne K Y Lam; Ying Wong; Sammy W M Shiu
Journal:  Clin J Am Soc Nephrol       Date:  2020-02-19       Impact factor: 8.237

3.  The effectiveness and safety of modest exercise in Japanese patients with chronic kidney disease: a single-armed interventional study.

Authors:  Masami Hamada; Yoshinari Yasuda; Sawako Kato; Hiroki Arafuka; Motomitsu Goto; Mutsuharu Hayashi; Etsuko Kajita; Shoichi Maruyama
Journal:  Clin Exp Nephrol       Date:  2015-07-25       Impact factor: 2.801

4.  Serum metabolomic profiles from patients with acute kidney injury: a pilot study.

Authors:  Jinchun Sun; Melissa Shannon; Yosuke Ando; Laura K Schnackenberg; Nasim A Khan; Didier Portilla; Richard D Beger
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-03-06       Impact factor: 3.205

5.  Risk factors: HDL-cholesterol levels and mortality in patients with ESRD.

Authors:  Nosratola D Vaziri
Journal:  Nat Rev Nephrol       Date:  2014-09-23       Impact factor: 28.314

Review 6.  Statins in the management of dyslipidemia associated with chronic kidney disease.

Authors:  Murray Epstein; Nosratola D Vaziri
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

Review 7.  Role of HDL dysfunction in end-stage renal disease: a double-edged sword.

Authors:  Hamid Moradi; Nosratola D Vaziri; Moti L Kashyap; Hamid M Said; Kamyar Kalantar-Zadeh
Journal:  J Ren Nutr       Date:  2013-05       Impact factor: 3.655

8.  Post-transcriptional nature of uremia-induced downregulation of hepatic apolipoprotein A-I production.

Authors:  Hamid Moradi; Hamid M Said; Nosratola D Vaziri
Journal:  Transl Res       Date:  2012-12-03       Impact factor: 7.012

Review 9.  Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.

Authors:  Nosratola D Vaziri; Keith C Norris
Journal:  Blood Purif       Date:  2013-01-22       Impact factor: 2.614

Review 10.  Cholesterol Metabolism in CKD.

Authors:  Allison B Reiss; Iryna Voloshyna; Joshua De Leon; Nobuyuki Miyawaki; Joseph Mattana
Journal:  Am J Kidney Dis       Date:  2015-09-01       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.